Skip to content

A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil in Patients With Psoriasis Vulgaris

A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil in Patients With Psoriasis Vulgaris. This study has been completed. Sponsor: LEO Pharma. Information provided by (Responsible Party): LEO Pharma. Bethesda, Md., Aug. 18 — ClinicalTrials.gov registry received information related to the study (NCT02518048) titled ‘A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil(R) in Patients With Psoriasis Vulgaris’ on Aug. New P2 trial; A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil in Patients With Psoriasis Vulgaris (clinicaltrials.gov) – Aug 7, 2015 – P2; N35; Not yet recruiting; Sponsor: LEO Pharma.

A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil   in Patients With Psoriasis Vulgaris 2Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus clinicaltrials:NCT00582881. A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil in Patients With Psoriasis Vulgaris. A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil in Patients With Psoriasis Vulgaris.

Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine. A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil in Patients With Psoriasis Vulgaris. SEARCHSTUDY LEO Pharma STUDY:SPONSOR-COLLABORATORS Clinical Trials, 158 Results, Page 1. Increased risk of migraine in patients with psoriasis: A Danish nationwide cohort study.

About: Connective Tissue Diseases

Skin And Tissue Diseases